AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment
AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). This approval marks a significant advancement in the treatment of this rare and chronic form of leukemia, offering new hope to […]